Decentralized production of anti-CD19 CAR T cells with CliniMACS Prodigy®: practical experience and cost analysis in India | Bone Marrow Transplant – Nature.com | CarTailz

  • Jain T, Litzow MR. No free riders: management of toxicities of novel immunotherapies in ALL, including financial ones. Blood Adv. 2018;2:3393-403.

    Article CAS PubMed PubMed CentralGoogle Scholar

  • Tran G, Zafar SY. Financial toxicity and implications for cancer treatment in the age of molecular and immunotherapies. Ann Transl. Med. 2018;6:166.

    Article PubMed PubMed CentralGoogle Scholar

  • Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA, et al. Acute myeloid leukemia: challenges and real data from India. Br J Haematol. 2015;170:110-7.

    Article PubMed PubMed CentralGoogle Scholar

  • Jackson Z, Roe A, Sharma AA, Lopes FBTP, Talla A, Kleinsorge Block S, et al. Automated production of autologous CD19 CAR-T cells for the treatment of non-Hodgkin’s lymphoma. front immunol. 2020;11:1941. https://doi.org/10.3389/fimmu.2020.01941.

  • Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B et al. Closed system production of CD19 and CD20/19 dual-targeted chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. cytotherapy. 2018;20:394-406.

    Article CAS PubMedGoogle Scholar

  • Ran T, Eichmüller SB, Schmidt P, Schlander M. Costs of decentralized CAR-T cell production in an academic, non-profit setting. Int J Cancer. 2020;147:3438-45.

    Article CAS PubMed Google Scholar

  • Maschan M, Caimi PF, Reese-Koc J, Sanchez GP, Sharma AA, Molostova O, et al. Multi-site, point-of-care anti-CD19 CAR T cells induce high rates of remission in patients with B-cell malignancy. Nat Commun. 2021;12:7200.

    Article CAS PubMed PubMed CentralGoogle Scholar

  • Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, et al. Prophylactic tocilizumab prior to anti-CD19 CAR T-cell therapy in non-Hodgkin lymphoma. 2021;12:745320. https://doi.org/10.3389/fimmu.2021.745320.

  • Lock D, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser T, et al. Automated production of potent CD20-targeted chimeric antigen receptor T cells for clinical use. Hum Gene Ther. 2017;28:914-25.

    Article CAS PubMed Google Scholar

  • Gattinoni L, Lugli E, Ji Y Pos Z, Paulos CM, Quigley MF et al. A subset of human memory T cells with stem cell-like properties. Nat Med 2011;17:1290-7.

    Article CAS PubMed PubMed CentralGoogle Scholar

  • Biasco L, Scala S, Basso Ricci L, Dionisio F, Baricordi C, Calabria A, et al. In vivo human T-cell tracking reveals decades-long survival and activity of genetically engineered memory T-stem cells. Scientific Transl. Med. 2015;7:273ra13.

    Article PubMedGoogle Scholar

  • Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Investig. 2008;118:294-305.

    Article CAS PubMedGoogle Scholar

  • Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy in chronic lymphocytic leukemia. Nat Med 2018;24:563-71.

    Article CAS PubMed PubMed CentralGoogle Scholar

  • Köhl U, Arsenieva S, Holzinger A, Abken H. CAR-T cells in studies: current achievements and challenges that remain in engineering modified T cells for clinical applications Hum Gene Ther. 2018;29:559-68.

    Article PubMedGoogle Scholar

  • Wang X, Rivière I. Clinical manufacture of CAR-T cells: basis of a promising therapy. Mol Ther Oncolytics. 2016;3:16015.

    Article CAS PubMed PubMed CentralGoogle Scholar

  • Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, et al. Rapid generation of non-activated potent CAR-T cells. Nat Biomed Eng. 2022;6:118-28.

    Article CAS PubMed PubMed CentralGoogle Scholar

  • Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston ICD, et al. Automated production of chimeric antigen receptor T cells for adoptive immunotherapy with CliniMACS Prodigy. cytotherapy. 2016;18:1002-11.

    Article CAS PubMedGoogle Scholar

  • Bach PB, Giralt SA, Saltz LB. FDA Approval of Tisagenlecleucel: Promise and Complexity of a $475,000 Cancer Drug. JAMA. 2017;318:1861-2.

    Article PubMedGoogle Scholar

  • Leave a Comment